Strong Sales Growth
Zimmer Biomet reported mid-single-digit sales growth in Q3, marking the 11th consecutive quarter of such growth, with particularly strong performance in knees, hips, and S.E.T. segments.
Positive Pricing Environment
Consolidated pricing was positive for the third consecutive quarter, driven by improved market conditions and strategic pricing governance.
Product Innovation and Launches
The company highlighted a robust product pipeline with over 50 planned launches, including the Z1 triple taper hip stem and ROSA surgical platforms, which are expected to drive future growth.
Improved ERP Impact Outlook
The ERP-related sales impact was revised down to 60-80 basis points, better than the initially expected 100 basis points, with normalization expected by year-end.
Strong Cash Flow and Share Buybacks
Zimmer Biomet generated $310 million in free cash flow and repurchased approximately $600 million in shares, reaffirming its commitment to return capital to shareholders.